oseltamivir has been researched along with Body Weight in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Liu, H; Tang, CC; Xiang, TN; Ye, XL; Zheng, YJ | 1 |
| Bhardwaj, R; Clinch, B; Gibiansky, L; Grimsey, P; Parrott, NJ; Ravva, P; Sturm, S; Zwanziger, E | 1 |
| Itoh, Y; Kanazu, T; Kitano, M; Kobayashi, M; Kodama, M; Sato, A; Yoshida, R | 1 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Kamal, MA; Rayner, CR; Reynolds, DK; Smith, PF; Subramoney, V; Van Wart, SA | 1 |
| Abed, Y; Boivin, G; Pizzorno, A; Rhéaume, C | 1 |
| Acosta, EP; Ampofo, K; Clinch, B; Gibiansky, L; Jester, P; Kamal, MA; Kimberlin, DW; Niranjan, V; Rath, B; Rayner, CR; Sánchez, PJ; Whitley, R | 1 |
| Bae, JY; Baek, LJ; Cheong, HJ; Heo, J; Hwang, MW; Jang, SI; Kim, D; Kim, H; Kim, JI; Lee, I; Lee, S; Park, MS; Park, S; Song, JW; Song, KJ | 1 |
| Amnuoypol, S; Mungmee, C; Nagai, T; Wirotesangthong, M; Yamada, H | 1 |
| Brakenhoff, JP; Cornelissen, LA; Friesen, RH; Goudsmit, J; Koldijk, MH; Koudstaal, W; Weverling, GJ | 1 |
| Lodise, TP; Pai, MP | 1 |
| Bansod, S; Bellot, M; Breidenbach, A; Donner, B; Freichel, C; Gand, L; Gatti, S; Hoffmann, G; Körner, A; Prinssen, EP; Singer, T; Weiser, T | 1 |
| Hayashi, K; Hayashi, T; Lee, JB; Nakano, T | 1 |
| Bush, K; Goloubeva, OG; Govorkova, EA; Leneva, IA; Webster, RG | 1 |
| Carr, JA; Hayden, FG; Ives, JA; Kelly, L; Lambkin, R; Mendel, DB; Oxford, JS; Roberts, NA; Tai, CY | 1 |
1 review(s) available for oseltamivir and Body Weight
| Article | Year |
|---|---|
Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Area Under Curve; Body Weight; Child; Child, Preschool; Clinical Trials as Topic; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Infant; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Theoretical; Oseltamivir; Predictive Value of Tests; Young Adult | 2013 |
1 trial(s) available for oseltamivir and Body Weight
| Article | Year |
|---|---|
Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.
Topics: Adult; Antiviral Agents; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Obesity; Oseltamivir; Treatment Outcome; Young Adult | 2011 |
12 other study(ies) available for oseltamivir and Body Weight
| Article | Year |
|---|---|
[Reduning Injection protects flu-infected mice by inhibiting infiltration of inflammatory cells in lung and down-regulating cytokine storm].
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemokine CCL5; Chemokine CXCL10; Cytokine Release Syndrome; Cytokines; Drugs, Chinese Herbal; Female; Imiquimod; Interleukin-10; Interleukin-6; Lung; Mice; Mice, Inbred C57BL; Oseltamivir; Phosphates; RNA; RNA, Messenger; Tumor Necrosis Factor-alpha; Weight Loss | 2022 |
Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants.
Topics: Adult; Age Factors; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Infant; Infant, Newborn; Kidney; Male; Models, Biological; Oseltamivir | 2020 |
Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Body Weight; Cyclopentanes; Cyclophosphamide; Drug Administration Schedule; Female; Guanidines; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Injections, Intravenous; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Phosphorous Acids; Survival Analysis; Treatment Outcome | 2013 |
Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.
Topics: Animals; Antiviral Agents; Body Weight; Disease Models, Animal; Drug Therapy, Combination; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Lung; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome; Viral Load; Zanamivir | 2014 |
The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.
Topics: Administration, Oral; Age Factors; Antiviral Agents; Biological Availability; Biotransformation; Body Weight; Carboxylic Acids; Computer Simulation; Drug Dosage Calculations; Drug Resistance, Viral; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Linear Models; Male; Models, Biological; Oseltamivir | 2014 |
Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Body Weight; Cyclopentanes; Dogs; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Female; Guanidines; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred DBA; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Survival Rate | 2014 |
Effects of Clinacanthus siamensis leaf extract on influenza virus infection.
Topics: Acanthaceae; Animals; Antibodies, Viral; Antiviral Agents; Body Weight; Cell Line; Female; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Plant Extracts; Plant Leaves; Plants, Medicinal | 2009 |
Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Body Weight; Female; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Severity of Illness Index; Survival Analysis | 2009 |
Absence of central nervous system and hypothermic effects after single oral administration of high doses of oseltamivir in the rat.
Topics: Administration, Oral; Animals; Antiviral Agents; Body Temperature; Body Weight; Brain; Central Nervous System; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Hypothermia; Male; Oseltamivir; Rats; Rats, Sprague-Dawley | 2012 |
Anti-influenza A virus characteristics of a fucoidan from sporophyll of Undaria pinnatifida in mice with normal and compromised immunity.
Topics: Animals; Antiviral Agents; Body Weight; Disease Models, Animal; Immunocompromised Host; Influenza A virus; Mice; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Polysaccharides; Survival Analysis; Treatment Outcome; Undaria; Virus Replication | 2013 |
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Body Weight; Brain; Cyclopentanes; Disease Models, Animal; Dogs; Female; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Virus Replication; Zanamivir | 2001 |
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
Topics: Acetamides; Amino Acid Substitution; Animals; Antiviral Agents; Body Weight; Cell Line; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Fever; Humans; In Vitro Techniques; Inflammation; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Oseltamivir; Sequence Analysis, DNA; Virus Replication | 2002 |